Privi Speciality Chemicals reported a strong financial year with consolidated revenue rising to ₹2,563.69 crore and Profit After Tax surging to ₹316.72 crore. The company plans capacity expansion and aims for ₹5,000 crore revenue by FY29-30.
Privi Speciality Chemicals Reports Strong FY26 Growth, Targets ₹5,000 Crore Revenue
Consolidated Revenue from Operations for FY 2025-26 stood at ₹2,563.69 crore, a significant increase from ₹2,101.19 crore in FY 2024-25. Profit After Tax (PAT) also saw a substantial jump to ₹316.72 crore from ₹184.75 crore in the previous fiscal year. Earnings Per Share (EPS) grew to ₹81.08 from ₹47.30.
Reader Takeaway: Strong profit growth driven by speciality molecules; raw material costs are a key concern.
What just happened
Privi Speciality Chemicals Limited has announced its financial results for the fiscal year 2025-26. The company achieved consolidated revenue of ₹2,563.69 crore and a consolidated Profit After Tax of ₹316.72 crore. This performance reflects a notable increase in both top-line and bottom-line figures compared to the previous fiscal year.
Why this matters
These results indicate robust growth and improved profitability for Privi Speciality Chemicals. The increase in revenue is attributed to sustained demand for its core products, successful commercialisation of new speciality molecules, and an enhanced product mix. The company's consistent EBITDA margins above 20% for three consecutive years highlight operational efficiency.
The backstory
Privi Speciality Chemicals has been focused on expanding its product portfolio and manufacturing capabilities. The company has been working on backward integration and developing new speciality chemicals to cater to global demand. The proposed amalgamation of its subsidiaries, Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited, aims to streamline operations.
What changes now
The company is embarking on a significant expansion plan, the '5K:1K Vision', aiming for ₹5,000 crore in revenue and over ₹1,000 crore in EBITDA by FY 2029-30. This includes increasing manufacturing capacity from 48,000 MTPA to 72,000 MTPA by September 2028. The PRIGIV joint venture with Givaudan received a ₹50 crore equity infusion to support its growth and achieved positive PAT in Q4 FY26.
Risks to watch
The company's substantial export orientation, accounting for 67% of its revenue, makes it vulnerable to geopolitical risks, including shifts in global trade policies and potential disruptions to trade routes. Furthermore, its dependence on raw materials like Crude Sulphate Turpentine (CST) exposes it to volatility in global prices and supply chain fluctuations.
Peer comparison
(No specific peer data available in the filing)
Context metrics (time-bound)
- Consolidated Revenue from Operations FY 2025-26: ₹2,563.69 crore
- Consolidated Profit After Tax FY 2025-26: ₹316.72 crore
- Consolidated EPS FY 2025-26: ₹81.08
- Standalone EBITDA FY 2025-26: ₹665.45 crore
- Manufacturing Capacity Expansion target: 72,000 MTPA by September 2028
- Long-term Revenue Target: ₹5,000 crore by FY 2029-30
What to track next
Investors should closely monitor the progress of the proposed amalgamation of subsidiaries for potential synergies. Tracking the ramp-up of new production facilities and the company's ability to navigate raw material price volatility and geopolitical risks will be crucial.